DFDA

Methotrexate

Treatment for Interstitial Lung Disease And Pulmonary Sarcoidosis

Typical Dosage: 10-25 mg once weekly

Effectiveness
58%
Safety Score
30%
Clinical Trials
2
Participants
4K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
10-25 mg once weekly
Time to Effect
2-3 months
Treatment Duration
1-2 years (or longer)
Evidence Quality
MODERATE
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$750
Side Effect Mgmt:$300
Total Annual:$1,250
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
QALYs Gained
Outcome-Based Costs
Cost per Responder
$2,083
Cost per Remission
$4,167
Methotrexate Outcomes

for Interstitial Lung Disease And Pulmonary Sarcoidosis

Efficacy Outcomes
Overall Effectiveness
+58%
Response Rate
+60%
Remission Rate
+30%
Common Side Effects
Nausea
+25%
Fatigue
+15%
Liver enzyme elevation
+15%
Oral ulcers
+8%
Myelosuppression (rare)
+2%

Sources:

nih.gov
sarcoidosisnews.com
respiratory-therapy.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Methotrexate in Interstitial Lung Disease And Pulmonary Sarcoidosis

Effectiveness of Methotrexate Versus Prednisone as First-line Therapy for Pulmonary Sarcoidosis

NCT04314193ACTIVE NOT RECRUITINGPHASE4
View Study
138 participants
INTERVENTIONAL
's-Hertogenbosch, Netherlands +16 more
Started: Jun 1, 2020